Genedx Holdings Stock Earnings Reports

GeneDx reported Q1 2026 results with strong volume growth but lower-than-expected revenue. Key operational highlights: test result volume grew 34% year-over-year to 27,488 tests; exome and genome revenue was $90.6M (up 27%); total revenue was $102.3M; adjusted gross margin ~69%; adjusted net loss of $8.2M. The revenue shortfall (~$12M vs. expectations) was attributed to (1) a lower-than-expected blended average reimbursement rate (ARR) for exome/genome driven primarily by product mix (not contractual price changes) and parental-comparator mix shifts, and (2) softer-than-expected performance from non-core lines (Fabric and biopharma), including timing delays and a $31.3M non-cash impairment related to Fabric. Management updated full-year guidance to $475M–$490M revenue, at least 30% exome/genome volume growth (~126,400 tests), exome/genome revenue growth of at least 20%, adjusted gross margins ~70%, and a return to adjusted profitability for the full year (with Q2 adjusted net loss ~ $5M and moving back to adjusted profitable in Q3). Actions taken: $25M of OpEx reductions (re-phasing hires, marketing, some R&D), tighter channel and revenue-cycle management, acceleration of market-access efforts, optimization of genome COGS (AI/automation), and improved forecasting rigor. Strategic posture: focus on core diagnostic business (exome + genome), leveraging GeneDx Infinity dataset, pushing genome adoption (currently ~40–45% of outpatient/genome mix), and treating Fabric’s interpretation-as-a-service as primarily an international opportunity while maintaining biopharma/data as upside as deals mature. Management emphasized that the ARR gap is expected to improve over time as coverage expands, revenue-cycle processes are optimized, and scale reduces COGS; they view the updated guide as more conservative and executable, anchored in higher-confidence channels.